

UNIVERSITÀ DEGLI STUDI DI MILANO

selezione pubblica per n._1_ posto/i di Ricercatore a tempo determinato ai sensi dell'art.24, comma 3, lettera b) della Legge 240/2010 per il settore concorsuale 05/G1, Farmacologia,

Farmacologia Clinica e Farmacognosia

settore scientifico-disciplinare BIO/14

presso il Dipartimento di Scienze Farmacologiche e Biomolecolari,

(avviso bando pubblicato sulla G.U. n. 7 del 25.01.2019 del) Codice concorso 3972

[Nome e cognome] CURRICULUM VITAE

INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)

COGNOME	CATTANEO
NOME	ANNAMARIA
DATA DI NASCITA	[23, LUGLIO, 1979]

**INSERIRE IL PROPRIO CURRICULUM
(non eccedente le 30 pagine)**

PERSONAL INFORMATION

Family name, First name: **Cattaneo Annamaria**

Date of birth: **23/07/1979**

Nationality: **Italian**

SCOPUS AUTHOR ID 55136377000

ORCID ID 0000-0002-9963-848X

RESEARCHER ID K-5847-2016

H Index: 26

EDUCATION

2009 PhD Degree in Molecular Genetics applied to Biomedical Sciences Genetic Department, School of Medicine, Univ. of Brescia, Brescia, Italy - Name of PhD Supervisor: Prof. Massimo Gennarelli.

2004 Degree in Pharmaceutical Biotechnology, Pharm.D, School of Pharmacy, Univ. of Milano, Milano, Italy.

NATIONAL SCIENTIFIC HABILITATION

April 2018

Dr. CATTANEO has obtained the national scientific qualification to ASSOCIATE PROFESSOR, sector of competition 05 / G1 - Pharmacology, Clinical Pharmacology and Pharmacognosy, scientific discipline sector BIO 14 - Pharmacology in the field of National Scientific Habilitation 2018 (validity: from 10/04/2018 to 10/04/2024).

CURRENT POSITION(S)

- 2016 –to date Head of the Biological Psychiatry Laboratory, IRCCS Fatebenefratelli Institute, Brescia, Italy;
- 2013 to date joint position as Researcher at the Dept. of Psychological Medicine, Institute of Psychiatry, King's College London.

PREVIOUS POSITIONS

- 2015-16 Research Group Leader at the IRCCS Fatebenefratelli Institute, Brescia, Italy; joint position as Researcher at the Institute of Psychiatry, Dept. of Psychological Medicine, King's College London.
- 2013-14 Post-doc Researcher at the IRCCS San Giovanni di Dio, Fatebenefratelli Brescia, Italy; joint position as Researcher at the Dept. of Psychological Medicine, Institute of Psychiatry, King's College London.
- 2010-12 Post-doc Researcher, Department of Psychological Medicine, Institute of Psychiatry, King's College London.
- 2009-10 Post-doc Researcher, IRCCS Centre, Brescia, Italy.
- 2004-08 PhD Student, Dept. of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy.
- 2002-04 Undergraduate student at the Centre of Neuropharmacology, Dept. of Pharmacological Sciences, University of Milan, Italy.

FELLOWSHIPS

- 2010-12 Post-doc Fellowship, Section of Perinatal Psychiatry & Stress Psychiatry and Immunology, Dept of Psychological Medicine, Institute of Psychiatry, King's College London.
- 2004-2010 4 years Fellowship for PhD Program, Dept of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy.

PRIZES/AWARDS

- 2017 British Psychopharmacology Association Award (BAP), Harrogate, London, July 2017.
- 2016 Young Investigator Travel Award, Society of Biological Psychiatry Meeting, Atlanta.
- 2016 Veronesi Fellowship on "Depression in the mothers during pregnancy and its transmission to the next generation: role of epigenetic changes" in collaboration with Dr. Elisabeth Binder at the Max-Planck Institute, Munich, Germany.
- 2015 Award for Young Investigator Scientist, 28th ECNP Congress, Amsterdam.
- 2014 BRC Travel Award, PNIRS Conference with Oral Presentation, Philadelphia.
- 2014 Rafaelsen Young Investigator's Award, CINP 2014, Vancouver, Canada.
- 2013 Travel and Oral Presentation Award, Pharmacogenetics in Psychiatry Meeting, Hollywood.
- 2012 ECNP Travel Award Winner, 25th ECNP Congress, Vienna, Austria.

SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS

- 2017-18 1 PhD Student (Institute of Psychiatry, King's College London);
 4 Master Students (Dept. of Pharmacological and Biomolecular Sciences, University of Milan);
 3 post doc researchers (IRCCS San Giovanni di Dio, Fatebenefratelli Brescia);
 3 young researchers (IRCCS San Giovanni di Dio, Fatebenefratelli Brescia);

- 2016-17 4 Master Students (Dept. of Pharmacological and Biomolecular Sciences, University of Milan);
3 Postdoc Fellows (IRCCS San Giovanni di Dio, Fatebenefratelli Brescia);
1 PhD Student, Master Students (Institute of Psychiatry, King's College London);
- 2015-16 2 Postdoc Fellows (IRCCS San Giovanni di Dio, Fatebenefratelli Brescia);
- 2015-16 2 Master Students (Dept. of Pharmacological and Biomolecular Sciences, University of Milan);
- 2014-15 3 Master Students (Dept. of Pharmacological and Biomolecular Sciences, University of Milan);
- 2013-14 2 Master Students (Dept. of Pharmacological and Biomolecular Sciences, University of Milan).

ORGANISATION OF SCIENTIFIC MEETINGS

Participation to the Organization of two editions (November 2015 and April 2017) of the Conference: "*The effect of gut bacteria on the brain*" Geneva, Switzerland;

Scientific Organizer of the meeting: "*Role of the gut microbiome in neuropsychiatric and neurodegenerative diseases*", Brescia, September 2018.

INSTITUTIONAL RESPONSIBILITIES

2014-15 Organizer of Internal Seminars, IRCCS Fatebenefratelli Institute, Brescia, Italy.

COMMISSIONS OF TRUST

- 2018 PhD reviewer, University of Verona;
- 2016-18 Review panel member, ERC grants;
- 2017-to date Scientific Advisory Board Panel, European College of Neuropsychopharmacology;
- 2016- to date International Scientific Advisory Board of the Swiss Consortium on the Gut Microbiota and Alzheimer's disease, University of Geneva, Switzerland;
- 2016- to date ECNP Scientific Committee, ECNP;
- 2016 Awards Scientific Committee Member, CINP.

SEMINAR ACTIVITY WITHIN UNIVERSITY STUDY COURSES

Academic year	Degree course / Teaching class	University	Hours
AA 2013-2014	Degree in Pharmacy / Course of Applied Pharmacology (Prof. Riva)	School of Pharmacy, Università degli Studi di Milano	2
AA 2014-2015	Degree in Pharmacy / Course of Applied Pharmacology (Prof. Riva)	School of Pharmacy, Università degli Studi di Milano	2
AA 2015-2016	Degree in Pharmacy / Course of Applied Pharmacology (Prof. Riva).	School of Pharmacy, Università degli Studi di Milano	2
AA 2016-2017	Degree in Pharmacy / Course of Applied Pharmacology (Prof. Riva)	School of Pharmacy, Università degli Studi di Milano	2

AA 2017-2018	Degree in Pharmacy / Course of Pharmacology and Pharmacotherapy (Prof. Riva).	School of Pharmacy, Università' degli Studi di Milano	4
AA 2015-2016	Professional Development training program (Prof. Carmine M Pariante)	King's College London, Institute of Psychiatry	4
AA 2016-2017	Professional Development training program (Prof. Carmine M Pariante)	King's College London, Institute of Psychiatry	6
AA 2017-2018	Professional Development training program (Prof. Carmine M Pariante)	King's College London, Institute of Psychiatry	6

MEMBERSHIPS OF SCIENTIFIC SOCIETIES

2013-to date: Member of the International College of Neuropsychopharmacology;
2013-to date: Member of the Society of Biological Psychiatry;
2013 to date: Associated Member, Italian Society of Pharmacology;
2014 to date: Member, European College of Neuropsychopharmacology;
2014-to date: Member, European College of Neuropsychopharmacology;
2015 – to date: Associated Member, British Association of Psychopharmacology;
2014-15: Member, Society for Neuroscience; 2014-16: Member, International Society for Affective Disorders;
2004-10: Member, Italian Society of Neuropsychopharmacology.

MAJOR COLLABORATIONS

-PROF. CARMINE M PARIANTE, TOPIC: Stress and Inflammation; INSTITUTION: Stress, Psychiatry and Immunology Lab, Institute of Psychiatry, King's College, London.

-PROF. MARCO ANDREA RIVA, TOPIC: Animal models of prenatal Stress and stress in adolescence; INSTITUTION: Dept. of Pharmacological and Biomolecular Sciences, University of Milan.

-DR. ELISABETH BINDER, TOPIC: Epigenetic mechanisms and GXE interaction; INSTITUTION: Dept. of Translational Research in Psychiatry, Max-Planck Institute of Psychiatry, Munich, Germany.

-PROF. KATRI RÄIKKÖNEN and PROF. JARI LAHTI, TOPIC: GXE interaction studies in relation to stress early in Life, INSTITUTION: Institute of behavioral sciences, University of Helsinki, Finland.

-PROF. INA WEINER, TOPIC: animal models of infections during pregnancy or lactation and vulnerability for psychiatric diseases; INSTITUTION: The Stephen Harper Chair of Translational Neuroscience, School of Psychological Sciences, Sagol School of Neuroscience, Tel-Aviv University, Israel.

-PROF. FRANK BELLIVIER AND CYNTHIA MARIE-CLAIRE, TOPIC: Childhood trauma, bipolar disorders and peripheral biomarkers; INSTITUTION: Dept. de Psychiatrie et de Médecine Addictologique, Centres Experts Bipolaire et Dépression Résistante, Paris, France.

-PROF. GIOVANNI FRISONI, TOPIC: Gut microbiome in Alzheimer Disease; INSTITUTION: Memory Clinic of the Geneva University Hospital, Switzerland.

-PROF. URS MEYER, TOPIC: Poly:IC animal models of psychiatric disorders; INSTITUTION Institute of Veterinary Pharmacology and Toxicology, University of Zurich, Switzerland;

-PROF. JOHN CRYAN; TOPIC: Stress and Gut microbiome in animal models; INSTITUTION: Dept. of Anatomy & Neuroscience, University College Cork, Ireland.

-PROF. NADINE PROVENCAL; TOPIC: stress and epigenetics; INSTITUTION: Faculty of Health Sciences, Simon Fraser University

CAREER BREAKS: I had three maternity breaks for the birth of my three kids Diletta (05-09-2011), Sebastiano (01-08-2016) and Tommaso (16-10-2018)

ON-GOING GRANTS

<i>Project Title</i>	<i>Funding source</i>	<i>Amount</i>	<i>Period</i>	<i>Role of the PI</i>
Gut Microbiota and host epigenome Interplay in Alzheimer's Disease	Alzheimer Association	120.000 \$	2018-2020	Principal Investigator
Gut microbes, Neuroinflammation and Alzheimer's disease: determining the immunoregulatory role of gut microbiota on brain and behavior	COEN	240.000€	2018-2021	Principal Investigator of Italian research Unit
Optimizing response to Li treatment through personalized evaluations of individuals with bipolar I disorder: the R-Link Initiative	H2020	412.000 €	2018-2023	WP LEADER: responsible of leading all omics analyses (transcriptome, epigenome, miRNome and GWAS) and coordinating the bioinformatics analyses
Emotional Dysregulation in Adolescents: identification of clinical and biological risk factors	5X1000 to IRCCS	60.000€	2016-2018	Principal Investigator
Role of the gut microbiome in modulating inflammation and immune system in neurodegenerative and psychiatric disorders	Ministry of Health (Ricerca Corrente)	30.000€ per year	2015-2021	Principal Investigator
Role of stress and inflammation in the pathogenesis and pharmacological treatment of psychiatric disorders	Ministry of Health (Ricerca Corrente)	30.000€ per year	2015-2021	Principal Investigator

COMPLETED GRANTS

<i>Project Title</i>	<i>Funding source</i>	<i>Amount (Euros)</i>	<i>Period</i>	<i>Role of the PI</i>
Role of inflammation and related processes in the development, phenomenology and treatment of depression	ERANET NEURON	250.000€	2015-18	Principal Investigator of Italian research Unit

SUMMARY OF RESEARCH ACTIVITY

Author of **57** papers on peer review journals.

Invited speaker at Universities and special events: **5 Invitations**.

Organizer of symposia at national and International Congresses or invited speaker at International and National congresses: **33**.

Awards for Research activities: **8**

Grants: **7**

Total papers on peer-reviewed journals (including in press): **57**

% of first, second, last or corresponding author: **56,14 %**

Total number citations: **2482**

Average Impact factor: **5,605**

Average Impact factor top 10 publications: 10,529

H Index: **26** (Scopus)

LIST OF PUBLICATIONS:

1. A functional variant in the serotonin receptor 7 gene (*HTR7*), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression", Kelsoe J., Wei Y., McCarthy, M., Ren H., Carrillo-Roa T., Shekhtman T., DeModena A., Liu J., Leckband S.G., Mors O., Rietschel M., Henigsberg N, Cattaneo A, Binder EB, Aitchison K, *Molecular Psychiatry* 2019 *in press*.
IF=13.204
2. Transcriptional Signatures of Cognitive Impairment in Rat Exposed to Prenatal Stress. **Cattaneo A**, Begni V, Malpighi C, Cattane N, Luoni A, Pariante C, Riva MA. *Mol Neurobiol*. 2019 Feb 11. doi: 10.1007/s12035-019-1523-4. **IF= 5.076**
3. The relationship between physical activity, clinical and cognitive characteristics and BDNF mRNA levels in patients with severe mental disorders. Aas M, Djurovic S, Ueland T, Mørch RH, Laskemoen JF, Reponen EJ, **Cattaneo A**, Steen NE, Agartz I, Melle I, Andreassen OA. *World J Biol Psychiatry*. 2018 Dec 18:1-24. doi: 10.1080/15622975.2018.1557345. **IF= 3.713**
4. Genes associated with anhedonia: a new analysis in a large clinical trial (GENDEP). Ren H, Fabbri C, Uher R, Rietschel M, Mors O, Henigsberg N, Hauser J, Zobel A, Maier W, Dernovsek MZ, Sourey D, **Cattaneo A**, Breen G, Craig IW, Farmer AE, McGuffin P, Lewis CM, Aitchison KJ. *Transl Psychiatry*. 2018 Aug 13;8(1):150. doi: 10.1038/s41398-018-0198-3. **IF= 5.620**
5. Cattane N, Mora C, Lopizzo N, Borsini A, Maj C, Pedrini L, Rossi R, Riva MA, Pariante CM, **Cattaneo A**. Identification of a miRNAs signature associated with exposure to stress early in life and enhanced vulnerability for schizophrenia: New insights for the key role of miR-125b-1-3p in

- neurodevelopmental processes. *Schizophr Res.* 2018 Jul 26. pii: S0920-9964(18)30475-4. doi: 10.1016/j.schres.2018.07.030. **IF= 4.748**
6. Cattane N, Richetto J, **Cattaneo A.** Prenatal exposure to environmental insults and enhanced risk of developing Schizophrenia and Autism Spectrum Disorder: focus on biological pathways and epigenetic mechanisms. *Neurosci Biobehav Rev.* 2018 Jul 4. pii: S0149-7634(17)30972-7. doi: 10.1016/j.neubiorev.2018.07.001. Review. **IF=8.037**
 7. Labouesse M. A., Polesel M., Clementi E., Muller F., Markkanen E., Mouttet F., **Cattaneo A.** and Richetto J. MicroRNA expression profiling in the prefrontal cortex: putative mechanisms for the cognitive effects of adolescent high fat feeding. *Sci. Rep.* 2018, 8:8344. 10.1038/s41598-018-26631-x. **IF=4.122**
 8. Mora C., Zonca V., Riva M.A. & **Cattaneo A.** Blood biomarkers and treatment response in major depression, *Expert Review of Molecular Diagnostics*, 2018, 18:6, 513-529, DOI: 10.1080/14737159.2018.1470927. **IF=3.326**
 9. **Cattaneo A**, Cattane N, Malpighi C, Czamara D, Suarez A, Mariani N, Kajantie E, Luoni A, Eriksson JG, Lahti J, Mondelli V, Dazzan P, Räikkönen K, Binder EB, Riva MA, Pariante CM. FoxO1, A2M, and TGF- β 1: three novel genes predicting depression in gene X environment interactions are identified using cross-species and cross-tissues transcriptomic and miRNomic analyses. *Mol Psychiatry*. 2018 Jan 4. doi: 10.1038/s41380-017-0002-4. **IF=13.204**
 10. **Cattaneo A**, Pariante CM. Integrating 'Omics' Approaches to Prioritize New Pathogenetic Mechanisms for Mental Disorders. *Neuropsychopharmacology*. 2018 Jan;43(1):227-228. doi: 10.1038/npp.2017.221. **IF= 6.399**
 11. Rossetti A.C., Paladini M.S., Racagni G., Riva M.A, **Cattaneo A.** & Molteni R. Genome-wide analysis of LPS-induced inflammatory response in the rat ventral hippocampus: Modulatory activity of the antidepressant agomelatine, *The World Journal of Biological Psychiatry*, 2018, 19:5, 390-401, DOI: 10.1080/15622975.2017.1298839. **IF=3.713**
 12. Marizzoni M, Provasi S, **Cattaneo A**, Frisoni GB. Microbiota and neurodegenerative diseases. *Curr Opin Neurol.* 2017 Dec;30(6):630-638. doi: 10.1097/WCO.0000000000000496. **IF=5.307**
 13. Borsini A, **Cattaneo A**, Malpighi C, Thuret S, Harrison NA; MRC ImmunoPsychiatry Consortium, Zunszain PA, Pariante CM. Interferon-Alpha Reduces Human Hippocampal Neurogenesis and Increases Apoptosis via Activation of Distinct STAT1-Dependent Mechanisms. *Int J Neuropsychopharmacol.* 2017 Oct 10. doi: 10.1093/ijnp/pyx083. **IF=4.009**
 14. Bell JA, Kivimäki M, Bullmore ET, Steptoe A; MRC ImmunoPsychiatry Consortium, Carvalho LA. Repeated exposure to systemic inflammation and risk of new depressive symptoms among older adults. *Transl Psychiatry.* 2017 Aug 15;7(8):e1208. doi: 10.1038/tp.2017.155. **IF=5.620**
 15. Leday GGR, Vértés PE, Richardson S, Greene JR, Regan T, Khan S, Henderson R, Freeman TC, Pariante CM, Harrison NA; MRC Immunopsychiatry Consortium, Perry VH, Drevets WC, Wittenberg GM, Bullmore ET. Replicable and Coupled Changes in Innate and Adaptive Immune Gene Expression in Two Case-Control Studies of Blood Microarrays in Major Depressive Disorder. *Biol Psychiatry.* 2017 Jul 6. pii: S0006-3223(17)31617-7. doi: 10.1016/j.biopsych.2017.01.021. **IF=11.412**
 16. C. Scassellati, M. Costanzo, B. Cisterna, A. Nodari, M. Galiè, **A. Cattaneo**, V. Covi, G. Tabaracci, C. Bonvicini, M. Malatesta, Effects of mild ozonisation on gene expression and nuclear domains organization in vitro, *Toxicology in Vitro*, Volume 44, 2017, Pages 100-110, ISSN 0887-2333, <https://doi.org/10.1016/j.tiv.2017.06.021>. **IF=2.903**
 17. Lopizzo N., Tosato S., Begni V., Tomassi S., Cattane N., Barcella M., Turco G., Ruggeri M., Riva M.A., Pariante C.M. and **Cattaneo A.** Transcriptomic analyses and leukocyte telomere length measurement in subjects exposed to severe recent stressful life events. *Transl Psychiatry.* 2017 Feb 21;7(2):e1042. doi: 10.1038/tp.2017.5. **IF=5.620**

18. Cattane N, Rossi R, Lanfredi M, **Cattaneo A**. Borderline personality disorder and childhood trauma: exploring the affected biological systems and mechanisms. *BMC Psychiatry*. 2017;17:221. doi:10.1186/s12888-017-1383-2. **IF= 2.419**
19. Begni V, Riva M.A and **Cattaneo A**. Cellular and molecular mechanisms of the brain-derived neurotrophic factor in physiological and pathological conditions, (Lond). 2017 Jan 1;131(2):123-138. doi: 10.1042/CS20160009. Review **IF=4.654**
20. **Cattaneo A**, Cattane N, Begni V, Pariante CM, Riva MA. The human BDNF gene: peripheral gene expression and protein levels as biomarkers for psychiatric disorders. *Transl Psychiatry*. 2016 Nov 22;6(11):e958. doi: 10.1038/tp.2016.214. Review. **IF=5.620**
21. Volk N, Pape JC, Engel M, Zannas AS, Cattane N, **Cattaneo A**, Binder EB, Chen A. Amygdalar MicroRNA-15a Is Essential for Coping with Chronic Stress. *Cell Rep*. 2016 Nov 8;17(7):1882-1891. doi: 10.1016/j.celrep.2016.10.038. **IF=8.032**
22. Richetto J, Chesters R, **Cattaneo A**, Labouesse MA, Gutierrez AM, Wood TC, Luoni A, Meyer U, Vernon A, Riva MA. Genome-Wide Transcriptional Profiling and Structural Magnetic Resonance Imaging in the Maternal Immune Activation Model of Neurodevelopmental Disorders. *Cereb Cortex*. 2017 Jun 1;27(6):3397-3413. doi: 10.1093/cercor/bhw320. **IF=6.308**
23. **Cattaneo A**, Cattane N, Galluzzi S, Provasi S, Lopizzo N, Festari C, Ferrari C, Guerra UP, Paghera B, Muscio C, Bianchetti A, Volta GD, Turla M, Cotelli MS, Gennuso M, Prella A, Zanetti O, Lussignoli G, Mirabile D, Bellandi D, Gentile S, Belotti G, Villani D, Harach T, Bolmont T, Padovani A, Boccardi M, Frisoni GB; INDIA-FBP Group. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. *Neurobiol Aging*. 2016 Aug 31; 49:60-68. doi: 10.1016/j.neurobiolaging.2016.08.019. **IF= 5.153**
24. **Cattaneo A**.* Maffioletti E*, Rosso G., Maina G., Maj C., Gennarelli M, Dr, Tardito D., Bocchio-Chiavetto L. Peripheral whole blood microRNA alterations in major depression and bipolar disorder. *Journal of Affective Disorders*. *these authors contributed equally. *J Affect Disord*. 2016 Aug;200:250-8. doi: 10.1016/j.jad.2016.04.021. **IF= 3.786**
25. Hepgul N, **Cattaneo A**, Agarwal K, Baraldi S, Borsini A, Bufalino C, Forton D, Mondelli V, Nikkheslat N, Lopizzo N, Riva MA, Russell A, Hotopf M, CM Pariante. Transcriptomics in interferon-alpha treated patients identifies inflammation-, neuroplasticity- and oxidative stress-related signatures as predictors and correlates of depression". *Neuropsychopharmacology*. 2016 Sep;41(10):2502-11. doi: 10.1038/npp.2016.50. **IF=6.399**
26. **Cattaneo A**, Ferrari C, Uher R, et al. Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1 β mRNA Levels Accurately Predict Treatment Response in Depressed Patients. *International Journal of Neuropsychopharmacology*. 2016;19(10):pyw045. doi:10.1093/ijnp/pyw045. **IF=4.009**
27. Rosso, G., **Cattaneo, A.**, Zanardini, R., Gennarelli, M., Maina, G., Bocchio-Chiavetto, L. Glucose metabolism alterations in patients with bipolar disorder. *J Affect Disord*. 2015 Sep 15;184:293-8. doi: 10.1016/j.jad.2015.06.006. **IF= 3.786**
28. **Cattaneo, A.**, Riva, M.A. Stress-induced mechanisms in mental illness: A role for glucocorticoid signalling *J Steroid Biochem Mol Biol*. 2016 Jun;160:169-74. doi: 10.1016/j.jsbmb.2015.07.021. **IF=4.561**
29. Lopizzo, N., Chiavetto, L.B., Cattane, N., Plazzotta, G., Tarazi, F.I., Pariante, C.M., Riva, M.A., **Cattaneo, A**. Gene-environment interaction in major depression: Focus on experience-dependent biological systems *Front Psychiatry*. 2015 May 8;6:68. doi: 10.3389/fpsy.2015.00068. eCollection 2015.. **IF=3.532**
30. **Cattaneo, A.**, Macchi, F., Plazzotta, G., Veronica, B., Bocchio-Chiavetto, L., Riva, M.A., Pariante, C.M. Inflammation and neuronal plasticity: A link between childhood trauma and depression pathogenesis. *Front Cell Neurosci*. 2015 Mar 31;9:40. doi: 10.3389/fncel.2015.00040. eCollection 2015. **IF=4.300**

31. Valbonesi, S., Magri, C., Traversa, M., Faraone, S.V., **Cattaneo, A.**, Milanese, E., Valenti, V., Gennarelli, M., Scassellati, C. Copy number variants in attention-deficit hyperactive disorder: Identification of the 15q13 deletion and its functional role *Psychiatr Genet*. 2015 Apr;25(2):59-70. doi: 10.1097/YPG.0000000000000056. **IF= 1.586**
32. Horowitz MA, Wertz J, Zhu D, **Cattaneo A.**, et al. Antidepressant Compounds Can Be Both Pro- and Anti-Inflammatory in Human Hippocampal Cells. *International Journal of Neuropsychopharmacology*. 2015;18(3):pyu076. doi:10.1093/ijnp/pyu076. **IF= 4.009**
33. Aas, M., Haukvik, U.K., Djurovic, S., Tesli, M., Athanasiu, L., Bjella, T., Hansson, L., **Cattaneo, A.**, Agartz, I., Andreassen, O.A., Melle, I. Interplay between childhood trauma and BDNF val66met variants on blood BDNF mRNA levels and on hippocampus subfields volumes in schizophrenia spectrum and bipolar disorders *J Psychiatr Res*. 2014 Dec;59:14-21. doi: 10.1016/j.jpsychires.2014.08.011. **IF= 4.465**
34. Zunszain, P.A., Horowitz, M.A., **Cattaneo, A.**, Lupi, M.M., Pariante, C.M. Ketamine: Synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties *Mol Psychiatry*. 2013 Dec;18(12):1236-41. doi: 10.1038/mp.2013.87 **IF= 13.204**
35. Mondelli, V., Anacker, C., Vernon, A.C., **Cattaneo, A.**, Natesan, S., Modo, M., Dazzan, P., Kapur, S., Pariante, C.M. Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways. *Transl Psychiatry*. 2013 Jan 15;3:e208. doi: 10.1038/tp.2012.138. **IF= 5.620**
36. Di Nicola, M., **Cattaneo, A.**, Hepgul, N., Di Forti, M., Aitchison, K.J., Janiri, L., Murray, R.M., Dazzan, P., Pariante, C.M., Mondelli, V. Serum and gene expression profile of cytokines in first-episode psychosis *Brain Behav Immun*. 2013 Jul;31:90-5. doi: 10.1016/j.bbi.2012.06.010. **IF= 6.306**
37. Rybka, J., Kedziora-Kornatowska, K., Banaś-Leżańska, P., Majsterek, I., Carvalho, L.A., **Cattaneo, A.**, Anacker, C., Kedziora, J. Interplay between the pro-oxidant and antioxidant systems and proinflammatory cytokine levels, in relation to iron metabolism and the erythron in depression *Free Radic Biol Med*. 2013 Oct;63:187-94. doi: 10.1016/j.freeradbiomed.2013.05.019. **IF= 5.736**
38. Anacker, C., **Cattaneo, A.**, Musaelyan, K., Zunszain, P.A., Horowitz, M., Molteni, R., Luoni, A., Calabrese, F., Tansey, K., Gennarelli, M., Thuret, S., Price, J., Uher, R., Riva, M.A., Pariante, C.M. Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis. *Proc Natl Acad Sci U S A*. 2013 May 21;110(21):8708-13. doi: 10.1073/pnas.1300886110. **IF= 9.504**
39. Anacker, C., **Cattaneo, A.**, Luoni, A., Musaelyan, K., Zunszain, P.A., Milanese, E., Rybka, J., Berry, A., Cirulli, F., Thuret, S., Price, J., Riva, M.A., Gennarelli, M., Pariante, C.M. Glucocorticoid-related molecular signaling pathways regulating hippocampal neurogenesis *Neuropsychopharmacology*. 2013 Apr;38(5):872-83. doi: 10.1038/npp.2012.253. **IF= 6.399**
40. Hepgul, N., **Cattaneo, A.**, Zunszain, P.A., Pariante, C.M. Depression pathogenesis and treatment: What can we learn from blood mRNA expression? *BMC Med*. 2013 Feb 5;11:28. doi: 10.1186/1741-7015-11-28. **IF= 9.088**
41. **Cattaneo, A.**, Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K.J., Craig, I.W., Anacker, C., Zunszain, P.A., McGuffin, P., Pariante, C.M. Candidate genes expression profile associated with antidepressants response in the GENDEP study: Differentiating between baseline 'predictors' and longitudinal 'targets'. *Neuropsychopharmacology*. 2013 Feb;38(3):377-85. doi: 10.1038/npp.2012.191. **IF= 6.399**
42. Milanese, E., Minelli, A., Cattane, N., **Cattaneo, A.**, Mora, C., Barbon, A., Mallei, A., Popoli, M., Florio, V., Conca, A., Bignotti, S., Gennarelli, M. ErbB3 mRNA leukocyte levels as a biomarker for major depressive disorder. *BMC Psychiatry*. 2012 Sep 18;12:145. doi: 10.1186/1471-244X-12-145. **IF= 2.419**
43. Zunszain, P.A., Anacker, C., **Cattaneo, A.**, Choudhury, S., Musaelyan, K., Myint, A.M., Thuret, S., Price, J., Pariante, C.M. Interleukin-1 β : A new regulator of the kynurenine pathway affecting human

- hippocampal neurogenesis (2012) *Neuropsychopharmacology*.;37(4):939-49. doi: 10.1038/npp.2011.277. **IF=6.399**
44. Anacker, C., Zunszain, P.A., **Cattaneo, A.**, Carvalho, L.A., Garabedian, M.J., Thuret, S., Price, J., Pariante, C.M. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor (2011) *Mol Psychiatry*. 2011 Jul;16(7):738-50. doi: 10.1038/mp.2011.26. **IF=13.204**
 45. Zunszain, P.A., Anacker, C., **Cattaneo, A.**, Carvalho, L.A., Pariante, C.M. Glucocorticoids, cytokines and brain abnormalities in depression (2011) *Prog Neuropsychopharmacol Biol Psychiatry*. 2011 Apr 29;35(3):722-9. doi: 10.1016/j.pnpbp.2010.04.011. **IF=4.185**
 46. Mondelli, V., **Cattaneo, A.**, Murri, M.B., Forti, M.D., Handley, R., Hepgul, N., Miorelli, A., Navari, S., Papadopoulos, A.S., Aitchison, K.J., Morgan, C., Murray, R.M., Dazzan, P., Pariante, C.M. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: A pathway to smaller hippocampal volume *J Clin Psychiatry*. 2011 Dec;72(12):1677-1684. doi: 10.4088/JCP.10m06745. **IF=5.498**
 47. Gennarelli M, **Cattaneo A.** Genetic variations and association. *Int Rev Neurobiol*. 2010;94:129-51. doi: 10.1016/B978-0-12-384976-2.00006-X. Review. **IF=2.371**
 48. Fumagalli F, **Cattaneo A**, Caffino L, Ibba M, Racagni G, Carboni E, Gennarelli M, Riva MA. *Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate*. *Pharmacol Res*. 2010 Dec;62(6):523-9. doi: 10.1016/j.phrs.2010.07.009. **IF=4.408**
 49. **Cattaneo A.**, Sesta A., Calabrese F, Nielsen G., Riva M.A. and Gennarelli M. *The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment*. *Neuropsychopharmacology*. 2010 Jun;35(7):1423-8. doi: 10.1038/npp.2010.11. **IF=6.399**
 50. Calabrese F, Molteni R, **Cattaneo A**, Macchi F, Racagni G, Gennarelli M, Ellenbroek B, Riva MA. *Long term duloxetine treatment normalizes altered BDNF expression in serotonin transporter knock-out rats through the modulation of specific neurotrophin isoforms*. *Mol Pharmacol*. 2010 May;77(5):846-53. Epub 2010 Feb 16. **IF=3.987**
 51. **Cattaneo A.**, Bocchio-Chiavetto L., Zanardini R., Marchina E., Bellotti D., Milanesi E., Moraschi S., Calabrese F., Barlati S., Riva M.A. and Gennarelli M. *BDNF Val66Met polymorphism and protein levels in amniotic fluid*. *BMC Neurosci*. 2010 Feb 8;11:16. doi: 10.1186/1471-2202-11-16. **IF=2.173**
 52. Molteni R., **Cattaneo A.**, Calabrese F., Macchi F., Racagni G., Ellenbroek B. A., Gennarelli M. and Riva M.A. *Reduced function of sert is associated with decreased expression of the neurotrophin Brain-derived neurotrophic factor (BDNF) in rodents as well as in humans*. *Neurobiol Dis*. 2010 Mar;37(3):747-55. doi: 10.1016/j.nbd.2009.12.014 **IF=5.624**
 53. **Cattaneo A.**, Bocchio-Chiavetto L., Zanardini R., Milanesi E., Placentino A. and Gennarelli M. *Reduced peripheral BDNF levels are normalized by antidepressant treatment*. *Int J Neuropsychopharmacol*. 2010 Feb;13(1):103-8. doi: 10.1017/S1461145709990812. **IF=4.009**
 54. Molteni R, Calabrese F, **Cattaneo A**, Mancini M, Gennarelli M, Racagni G, Riva MA. *Acute stress responsiveness of the neurotrophin BDNF in the rat hippocampus is modulated by chronic treatment with the antidepressant duloxetine*. *Neuropsychopharmacology*. 2009 May;34(6):1523-32. Epub 2008 Nov 19. Erratum in: *Neuropsychopharmacology*. 2009 Aug; 34(9):2196. **IF=6.399**
 55. Musazzi L*, **Cattaneo A.***, Tardito D., Barbon A., Gennarelli M, Barlati S., Racagni G., Popoli M. *Early raise of BDNF in hippocampus suggests induction of posttranscriptional mechanisms by antidepressants*. *BMC Neurosci*. 2009 May 13;10:48. doi: 10.1186/1471-2202-10-48. *These authors have contributed equally. **IF=2.173**
 56. Calabrese F, Molteni R, Maj PF, **Cattaneo A**, Gennarelli M, Racagni G, Riva MA. *Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein*. *Neuropsychopharmacology*. 2007 Nov; 32(11):2351-9. Epub 2007 Feb 28. **IF=6.399**

57. Maj PF, Collu M, Fadda P, **Cattaneo A**, Racagni G, Riva MA. *Long-term reduction of brain-derived neurotrophic factor levels and signaling impairment following prenatal treatment with the cannabinoid receptor 1 receptor agonist (R)-(+)-[2, 3-dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo[1, 2, 3-de]-1, 4-benzoxazin-6-yl]-1-naphthalenylmethanone*. Eur J Neuro-Sci. 2007;25:3305–3311. **IF=2.941**

INVITED PRESENTATIONS TO INTERNATIONALLY ESTABLISHED CONFERENCES

Invited speaker at the AD/PD Conference, Turin, March 2018 Title of the Symposium: “Role of the gut microbiota in Alzheimer disease: evidences from preclinical and clinical studies”.

Invited speaker at the World Association for Stress Related and Anxiety Disorders (WASAD) Title of the Symposium: “Long lasting epigenetic signatures associated with enhanced vulnerability for depression by using omics and cross species approaches”.

Invited speaker at the British Association of Psychopharmacology (BAP 2017) Title of the Symposium: “Foxo1, A2M and TGFbeta: three novel genes predicting gene x environment Interactions are identified by using cross species and cross tissues transcriptomics and mirnomics analyses”.

Invited speaker at the XII Convegno Nazionale SIndem (2017) Title of the Symposium: “Role of gut microbiota in Alzheimer’s disease”.

Invited speaker at the 30th ECNP Congress, Paris (2017) Title of the Symposium: “Identification of a long lasting stress signature associated with enhanced vulnerability for depression by using ‘omics and cross species approaches”.

SYMPOSIUM ORGANIZER AND/OR SPEAKER AT INTERNATIONALLY ESTABLISHED CONFERENCES

2019

Speaker in the symposium: “Fluttuazioni ormonali, oscillazione del tono dell’umore, il file rouge dei trattamenti psicofarmacologici”, SINPF January 2019, Milan, Italy. Title of the talk: “Depressione in gravidanza e trasmissione della vulnerabilità nel bambino. Ruolo dell’inflammation e dell’asse HPA”.

2018

Speaker in the symposium: “Early adversity and inflammation in stress-related psychiatric disorders”, October 2018, Berlin, Germany. Title of the talk: “FoxO1 as novel vulnerability gene for GxE interaction in depression”.

Speaker in the symposium “Microbiome & Neuropsychiatry- Moving towards mechanisms” at the International College of Neuropsychopharmacology, CINP, June 2018, Wien, Austria. Title of the talk: “Gut microbiome pro-inflammatory and anti-inflammatory mediators in brain functioning and behaviour: identification of possible pathways and treatment strategies”.

Speaker in the symposium “Prenatal Stress and Fetal Programming of Health and Disease risk: Role of Epigenetic Mechanisms and Telomere Biology” at the 73rd Annual Scientific Convention “Biomarkers, Biomodels, and Psychiatric Disorders”, May 2018, New York City, New York, USA. Title of the talk: “Prenatal Depression Exposure and Enhanced Stress Responses in the offspring: Role of the Glucocorticoid-Mediated Epigenetic Changes”.

Speaker in the symposium “Molecular and brain imaging biomarkers of response to lithium treatment” at the 26th European Congress of Psychiatry. Title of the talk: “MiRNomics and Transcriptomics Combining Analyses in Lymphoblastoid Cell Lines of Bipolar Patients Identified Networks Associated With Treatment Response”.

Speaker in the symposium “Microbiome” at the AD/PD Conference, Turin, March 2018. Title of the talk: “Role Of The Gut Microbiota In Alzheimer Disease: Evidences From Preclinical And Clinical Studies”.

Speaker in the symposium “The role of epigenetics in early life stress and the risk of bipolar disorder” at the 20th annual conference of the International Society for Bipolar Disorder, ISBD, March 2018, Mexico City. Title of the talk: “miRNAs signatures as epigenetic mechanisms bringing the memory of childhood trauma and illness in patients with bipolar disorder: relationships with childhood trauma and Lithium treatment response”.

Speaker in the symposium “Biomarkers molecolari di stressful life events nei disturbi dell’umore: dall’identificazione alla terapia at the XXII congresso nazionale della società italiana di psicopatologia. Title of the talk: “FoxO1 come nuovo gene di vulnerabilità nel modello di malattia GXE della depressione”.

2017

Speaker in the symposium “Stress: epigenetics- synaptic changes- and pathophysiology ” at the National Congress of the Italian Neuroscience Society, SINS, October 2017 Ischia, Italy. Title of the talk: “Identification of a long lasting early in life stress signature associated with enhanced vulnerability for depression by using 'omics' and cross species approaches both in animals and in humans”.

Speaker in the symposium “Stress, development and epigenomics” at the World Association for Stress Related and Anxiety Disorders (WASAD) Congress, September 2017, Würzburg, Germany. Title of the talk: “Long lasting epigenetic signatures associated with enhanced vulnerability for depression by using ‘omics and cross species approaches”.

Speaker in the symposium “The role of stressful life events on shaping adult brain and genome toward psychopathology” at the 30th ECNP Congress of Applied and Translational Neuroscience, September 2017, Paris, France. Title of the talk: “Identification of a long lasting stress signature associated with enhanced vulnerability for depression by using ‘omics and cross species approaches”.

Speaker in the symposium “The stressed genome in affective disorders: a novel target for pharmacological intervention? at the 30th ECNP Congress of Applied and Translational Neuroscience, September 2017, Paris, France. Title of the talk: “Perinatal adversities and stress vulnerability in later life”.

Oral presentation at “Psychopharmacology Junior Non-Clinical Award oral presentation” at the British Association for Psychopharmacology Summer meeting, BAP, July 2017, Harrogate. Title of the talk: “FOXO1, A2M and TGFB1: three novel genes predicting depression in geneXenvironment interactions are identified using cross-species and cross-tissues transcriptomic and miRNomic analyses”.

Speaker in the symposium “Stress Vulnerability and resilience: Integrating Neural circuits, Molecular mechanisms, and Clinical Signatures” at Society of Biological Psychiatry 72nd Annual Meeting "Networks and Complexity in Biology, Brain and Behavior”, May 2017, San Diego, California, USA. Title of the talk: “Distinct miRNAs Signatures Associated with Stress Vulnerability and Stress Resilience in Childhood Trauma-Exposed Individuals”.

Speaker in the symposium “Childhood Trauma in Severe Mental Disorders: Clinical Expression and Mechanisms” at EPA 25th European Congress of Psychiatry, April 2017, Florence, Italy. Title of the talk: “Biomarkers and childhood trauma”.

Speaker in the conference “Brain Diseases & Gut Microbiota”, April 2017, Geneva, Switzerland. Title of the talk: “Gut bacteria profile and peripheral cytokines in amyloid positive Alzheimer’s disease”.

Speaker in the symposium “Neurodegeneration: brain & beyond” at XII Convegno Nazionale SIndem, March 2017, Florence, Italy. Title of the talk: “Role of gut microbiota in Alzheimer’s Disease”.

2016

Speaker in the Symposium “Inflammation and Depression: peripheral and central issue” at the XIX National Congress of the Italian Society of Neuropsychopharmacology, SINPF, October 2016, Acireale, Italy. Title of the talk: “Identification of a peripheral and central signature associated with stress and inflammation by using an integrated approach in animals and humans”.

Speaker in the Symposium “Intergenerational Transmission of Stress Exposure and Psychopathology: Focus on Clinical and Biological Correlates” at the Society of Biological Psychiatry 71st Annual Meeting, May 2016,

Atlanta, Georgia, USA. Title of the talk: “DNA Methylation and miRNAs Signatures as Epigenetic Mechanisms Bringing the Memory of Childhood Trauma and Illness”.

Oral presentation at Congresso della Società Italiana di Farmacologia, SIF, “The Stressed Brain: Psychopathologic Implications and Pharmacological Intervention”, March 2016, Milan, Italy. Title of the presentation: “Inflammatory related pathways and SGK1 signaling as targets of early life stressful events: role of DNA methylation and miRNAs”.

Speaker in the Symposium “Stress e neurosviluppo: meccanismi biologici e implicazioni cliniche” at 20° Congresso Nazionale SOPSI, February 2016, Milan, Italy. Title of the talk: “Esposizione ad eventi stressanti in adolescenza e vulnerabilità a sviluppare psicopatologie in età adulta: ruolo dell’asse HPA”.

2015

Speaker at the conference “Gut Feelings And Gut Thoughts: The Effect Of Gut Bacteria On The Brain, Alzheimer’s And Brain Amyloidosis”, November 2015, Geneva, Switzerland Title of the talk: “Brain amyloidosis and gut bacteria in humans”.

Speaker in the Symposium “Childhood trauma in severe mental disorders: clinical expression and mechanisms” at EPA 23rd European Congress of Psychiatry, March 2015, Wien, Austria. Title of the talk: “Biomarkers and childhood trauma”.

Speaker in the Symposium “Ruolo dello stress “reale o percepito” nella patogenesi e trattamento della depressione” . Title of the talk: “Ruolo dello stress nello sviluppo di depressione indotta da interferone”. 19° Congresso Nazionale SOPSI, February 2015, Milan, Italy.

Speaker in the Symposium “La vulnerabilità ai disturbi psichici: approcci innovativi per lo studio dell’interazione fra fattori ambientali e biologici” . Title of the talk: “Eventi di vita stressanti precoci e vulnerabilità per patologie psichiatriche: ruolo dell’epigenetica”. 19° Congresso Nazionale SOPSI, February 2015, Milan, Italy.

2014

Speaker in the Symposium “The Interplay between Genetics and Early Trauma in Severe Mental Disorders” at the XXII World Congress of Psychiatric Genetics, October 2014, Copenhagen, Denmark. Title of the talk: “Blood Transcriptomics as Tool to Identify the Long-Lasting effects of Childhood Trauma on Psychopathologies Development”.

Speaker in the Symposium “The Role of Inflammation in Perinatal Depression” at the International Marcé Society For Perinatal Mental Health Biennial Scientific Conference, September 2014, Swansea, Wales, UK. Title of the talk: “Immune-Relevant Brain Changes Associated with Early Life Stressful Events”.

Organizer and speaker in the Symposium “Long lasting stress-related changes in the brain and increased risk for psychiatric disorders” at 2014 BAP Summer Meeting Post-Doctoral Symposium, July 2014, Cambridge, UK. Title of the talk: “Identification of transcriptomic signatures and pathways induced by early life stressful events and associated with increased vulnerability for psychiatric disorders”.

Oral presentation at Congresso della Società Italiana di Farmacologia, SIF, “Mood Disorders: From Neurobiology To Novel Therapeutic Strategies”, March 2014, Modena, Italy. Title of the presentation: “Increased MIF and IL-1 β mRNA blood levels and childhood trauma events as accurate predictors of treatment response in depressed patients.”

2013

Speaker in the Symposium “Inflammation and vulnerability to neuropsychiatric disorders: molecular mechanisms and clinical outcomes” at the 36° Congresso della Società Italiana di Farmacologia, SIF, October 2013, Turin, Italy. Title of the talk: “Gene expression as predictors of antidepressant response in the GENDEP study”.

Speaker in the thematic meeting “Pharmacogenomics and Personalised Medicine in Psychiatry”, the International College of Neuropsychopharmacology (CINP), April 2013, Jerusalem, Israel. Title of the talk: “Inflammatory Biomarkers As Predictive Of Depression, Cognitive Function And Treatment Response”.

2012

Speaker in the Symposium "Stress e infiammazione nella vulnerabilità e nel trattamento dei disturbi dell'umore", 16° Congresso Nazionale SOPSI, February 2012, Rome, Italy. Title of the talk: “Infiammazione e depressione: meccanismi molecolari, predittori e target della risposta al trattamento”.

2009

Oral communication in “Psychopharmacology” at the 9th World Congress of Biological Psychiatry, June 2009, Paris, France; Title of the talk: “Reduced blood BDNF mRNA levels in depressed patients are normalized by antidepressant treatment”.

Data

23-02-2019

Luogo

CARVICO